The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Open accessAbstract
// Yue-Lun Zhang 1, 2 , Jin-Qiu Yuan 1, 2 , Kai-Feng Wang 3 , Xiao-Hong Fu 1, 2 , Xiao-Ran Han 1, 2 , Diane Threapleton 1 , Zu-Yao Yang 1, 2 , Chen Mao 1, 2 , Jin-Ling Tang 1, 2 1 Division of Epidemiology, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China 2 Shenzhen Municipal Key Laboratory for Health Risk Analysis, Shenzhen Research Institute of The Chinese University of Hong Kong, Shenzhen, Guangdong Province, China 3 Division of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, Guangdong Province, China Correspondence to: Chen Mao, email: maochen@cuhk.edu.hk Jin-Ling Tang, email: jltang@cuhk.edu.hk Keywords: non-small cell lung cancer, epidermal growth factor receptor, prevalence, systematic review, meta-analysis Received: May 17, 2016 Accepted: September 25, 2016 Published: October 12, 2016 ABSTRACT Objectives: Estimate the epidermal growth factor receptor ( EGFR ) mutation prevalence in all non-small cell lung cancer (NSCLC) patients and patient subgroups. Results: A total of 456 studies were included, reporting 30,466 patients with EGFR mutation among 115,815 NSCLC patients. The overall pooled prevalence for EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe. The pooled prevalence of EGFR mutation was higher in females (females vs. males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9), non-smokers (non-smokers vs. past or current smokers: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0), and patients with adenocarcinoma (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% CI: 3.6 to 4.8). Materials and Methods: PubMed, EMBASE, and the Cochrane Library were searched to June 2013. Eligible studies reported EGFR mutation prevalence and the association with at least one of the following factors: gender, smoking status and histology. Random-effects models were used to pool EGFR mutation prevalence data. Conclusion: This study provides the exact prevalence of EGFR mutations in different countries and NSCLC patient subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
McGuire, S. (2016) · Advances in Nutrition · doi:10.3945/an.116.012211 · Cited by 1,898
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M.-S., Sakurada, A., Cutz, J.-C., Zhu, C.-Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,830
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S., Danenberg, K., Domenichini, I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,551
Shi, Y., Au, J. S.-K., Thongprasert, S., Srinivasan, S., Tsai, C.-M., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G., & Yang, P.-C. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,551
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,228
Midha, A., Dearden, S. P., & McCormack, R. (2015) · Europe PMC (PubMed Central) · Cited by 1,050
Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.992 · Cited by 948
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Marchetti, A., Martella, C., Felicioni, L., Barassi, F., Salvatore, S., Chella, A., Camplese, P. P., Iarussi, T., Mucilli, F., Mezzetti, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.043 · Cited by 788
Han, S.-W., Kim, T.-Y., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., Oh, D.-Y., Kim, J. H., Kim, D.-W., Chung, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.388 · Cited by 768
Han, J.-Y., Park, K., Kim, S.-W., Lee, D. H., Kim, H. Y., Kim, H. T., Ahn, M. J., Yun, T., Ahn, J. S., Suh, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8456 · Cited by 736
Dearden, S., Stevens, J., Wu, Y.-L., & Blowers, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt205 · Cited by 646
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-303 · Cited by 581
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
Cohen, M. H., Johnson, J. R., Chen, Y.-F., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-7-461 · Cited by 445
Yoshizawa, A., Sumiyoshi, S., Sonobe, M., Kobayashi, M., Fujimoto, M., Kawakami, F., Tsuruyama, T., Travis, W. D., Date, H., & Haga, H. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182769aa8 · Cited by 436
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
Cataldo, V. D., Gibbons, D. L., Pérez-Soler, R., & Quintás-Cardama, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmct0807960 · Cited by 418
Jänne, P. A., Engelman, J. A., & Johnson, B. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.985 · Cited by 405
Chou, T.-Y., Chiu, C.-H., Li, L.-H., Hsiao, C.-Y., Tzen, C.-Y., Chang, K.-T., Chen, Y.-M., Perng, R.-P., Tsai, S.-F., & Tsai, C.-M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1981 · Cited by 317
D'Angelo, S. P., Pietanza, M. C., Johnson, M. L., Riely, G. J., Miller, V. A., Sima, C. S., Zakowski, M. F., Rusch, V. W., Ladanyi, M., & Kris, M. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6181 · Cited by 301
Azzoli, C. G., Temin, S., Aliff, T., Baker, S., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2774 · Cited by 285
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Taron, M., Gandara, D., Hirsch, F. R., Grunenwald, D., Popper, H., Smit, E., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1c8de · Cited by 284
Leighl, N. B., Rekhtman, N., Biermann, W. A., Huang, J., Mino-Kenudson, M., Ramalingam, S. S., West, H., Whitlock, S., & Somerfield, M. R. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3055 · Cited by 281
Shi, Y., Li, J., Zhang, S., Wang, M., Yang, S., Li, N., Wu, G., Liu, W., Liao, G., Cai, K., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143515 · Cited by 197
Self-citationRosell, R., Gervais, R., Vergnenégre, A., Massutí, B., Felip, E., Cardenal, F., Gómez, R. G., Pallarés, C., Sanchez, J. M., Porta, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7503 · Cited by 147
National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China
Xue, C., Hu, Z., Jiang, W., Zhao, Y., Xu, F., Huang, Y., Zhao, H., Wu, J., Zhang, Y., Zhao, L., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.014 · Cited by 114
Self-citationNomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinoma
Girard, N., Sima, C. S., Jackman, D. M., Sequist, L. V. D., Chen, H., Yang, J. C., Ji, H., Waltman, B. A., Rosell, R., Tarón, M., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00010111 · Cited by 113
Non-Small Cell Lung Cancer Collaborative Group (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007309.pub2 · Cited by 86
Choi, Y., Sun, J., Cho, J., Rampal, S., Han, J., Parasuraman, B. M., Güallar, E., Lee, G., Lee, J., & Shim, Y. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056011 · Cited by 79
Lopes, G. D. L., Jr., Segel, J. E., Tan, D. S. W., Do, Y. K., Mok, T. S. K., & Finkelstein, E. A. (2011) · Cancer · doi:10.1002/cncr.26372 · Cited by 67
Haneda, H., Sasaki, H., Lindeman, N. I., Kawano, O., Endo, K., Suzuki, E., Shimizu, S., Yukiue, H., Kobayashi, Y., Yano, M., et al. (2006) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyi228 · Cited by 66
Qian, X., Liu, J., Sun, Y., Wang, M., HuaiDing, L., Luo, G., Liu, X., Xiong, C., Liu, J., Liu, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8684 · Cited by 58
EGFR mutations in non‐small‐cell lung cancer among smokers and non‐smokers: A meta‐analysis
Ren, J., He, W., Yan, G., Jin, M., Yang, K., & Wu, G. (2011) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20680 · Cited by 51
Szumera‐Ciećkiewicz, A., Olszewski, W. T., Tysarowski, A., Kowalski, D. M., Głogowski, M., Krzakowski, M. J., SIEDLECKI, J. A., Wągrodzki, M., & Prochorec‐Sobieszek, M. (2013) · Europe PMC (PubMed Central) · Cited by 46
Impact of age on epidermal growth factor receptor mutation in lung cancer
Ueno, T., Toyooka, S., Suda, K., Soh, J., Yatabe, Y., Miyoshi, S., Matsuo, K., & Mitsudomi, T. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.006 · Cited by 40
Salto‐Tellez, M., Tsao, M., Shih, J., Thongprasert, S., Lü, S., Chang, G., Au, J. S. K., Chou, T., Lee, J. S., Shi, Y.-K., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227816a · Cited by 38
Wang, S., & Wang, Z. (2014) · Europe PMC (PubMed Central) · Cited by 31
Cited by
The global burden of lung cancer: current status and future trends
Leiter, A., Veluswamy, R. R., & Wisnivesky, J. P. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00798-3 · Cited by 1,477
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604
Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30144-x · Cited by 568
Wu, Y.-L., Lu, S., Cheng, Y., Zhou, C., Wang, J., Mok, T., Zhang, L., Tu, H.-Y., Wu, L., Feng, J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.006 · Cited by 357
Self-citationAdenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies
Succony, L., Rassl, D., Barker, A., McCaughan, F., & Rintoul, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102237 · Cited by 342
Metadata
- Authors
- Zhang, Y.-L., Yuan, J.-Q., Wang, K.-F., Fu, X.-H., Han, X.-R., Threapleton, D., Yang, Z.-Y., Mao, C., & Tang, J.-L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-10-12
- Volume
- 7
- Issue
- 48
- Pages
- 78985-78993
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2530508394
- Cited by
- 799
- References
- 46
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.